Opinion on  Genentech Inc (DNA)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Bullish on DNA ...

Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $83 Analysts' Targets Deutsche Bank Securities $83 Accumulate Thursday, June 19, 2008 RBC Capital Markets $84 Outperform Monday, February 25, 2008 Jefferies & Co. $78 Accumulate Monday, February 25, 2008 Lazard Capital Markets $87 Strong Buy Monday, February 25, 2008 Lehman Brothers $70 Equalweight Monday, February 25, 2008 Friedman, Billings, Ramsey & C $76 Hold Monday, February 25, 2008 UBS Securities $95 Add Monday, February 25, 2008 Rodman & Renshaw Inc. $90 Mkt Outperform Monday, February 25, 2008 Caris & Company $91 Above Average Monday, February 25, 2008 Broadpoint Capital $76 Buy Tuesday, January 15, 2008

Exclusive short term trade

Business: Genentech Inc, (DNA) Genentech, Inc. engages in the discovery, development, manufacture, and commercialization of biotherapeutics in the United States. It markets Avastin (bevacizumab) for treating metastatic cancer of the colon or rectum and metastatic non-squamous non-small cell lung cancer. The company also commercializes Rituxan (rituximab) to treat B-cell non-Hodgkin's lymphoma; Herceptin (trastuzumab) for treating node-positive breast cancer; and Lucentis (ranibizumab) to treat neovascular (wet) age-related macular degeneration. It markets Xolair (omalizumab) for adults and adolescents with asthma; Tarceva (erlotinib) for the treatment of metastatic non-small cell lung cancer, as well as in combination with gemcitabine chemotherapy for the first-line treatment of metastatic pancreatic cancer; and Nutropin and Nutropin AQ growth hormone products for treating growth hormone deficiency in children and adults, growth failure associated with chronic renal insufficiency prior to kidney transplantation, short stature associated with turner syndrome, and long-term treatment of idiopathic short stature. The company also offers Activase for acute myocardial infarction (heart attack), acute ischemic stroke (blood clots in the brain), and acute massive pulmonary embolism (blood clots in the lungs); TNKase (tenecteplase) to treat heart attack; and Cathflo Activase for the restoration of function to central venous access devices in adult and pediatric patients. In addition, it provides Pulmozyme for cystic fibrosis; and Raptiva (efalizumab) for treating chronic moderate-to-severe plaque psoriasis in adults. The company sells its products to wholesalers, specialty distributors, or directly to hospital pharmacies. It has collaborations with F. Hoffmann-La Roche; Biogen Idec, Inc.; Novartis Pharma AG; Tanox, Inc.; Altus; Seattle Genetics, Inc.; OSI Pharmaceuticals, Inc.; and XOMA, Ltd. The company was founded in 1975 and is headquartered in South San Francisco, California.

Business Sector : DNA has been assigned to the  Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.

Industry Group : DNA has been assigned to the  Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors

Value:  Value is a measure of a stock's current worth.  DNA has a current Value of $83.39 per share. Therefore, it is overvalued compared to its Price of $96.64 per share .  Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.

RV (Relative Value):  RV is an indicator of long-term price appreciation potential. DNA has an RV of 1.18, which is good on a scale of 0.00 to 2.00 . This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.

RS (Relative Safety):  RS is an indicator of risk. DNA has an RS rating of 1.32, which is very good on a scale of 0.00 to 2.00 . RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.

RT (Relative Timing):  RT is a fast, smart, accurate indicator of a stock's price trend. DNA has a Relative Timing rating of 1.31, which is very good on a scale of 0.00 to 2.00.   RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.

VST (VST-Vector):   VST is the master indicator for ranking every stock in the VectorVest database. DNA has a VST rating of 1.28, which is very good on a scale of 0.00 to 2.00.  VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.

Recommendation (REC) : VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. DNA has a Buy recommendation . REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.

Stop (Stop-Price) : Stop is an indicator of when to sell a long position or cover a short position.  DNA has a Stop of $85.79 per share . This is $10.85 below DNA's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.

GRT (Earnings Growth Rate):  GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. DNA has a forecasted Earnings Growth Rate of 17.00%, which VectorVest considers to be very good . GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (11.55%).

EPS (Earnings per Share):  EPS stands for leading 12 months Earnings Per Share.  DNA has a forecasted EPS of $3.72 per share . VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.

P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings.  DNA has a P/E of 25.98 . This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 31.98. P/E is computed daily using the formula: P/E = Price/EPS.

EY (Earnings Yield) : EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. DNA has an EY of 3.85 percent . This is above the current average of 3.14% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).

GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. DNA has a GPE rating of 0.66 .  High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.95%, the operative GPE ratio is 0.35. Therefore, DNA may be considered to be undervalued .

Dividend Analysis

DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. DNA does not pay a dividend .

DY (Dividend Yield): DY reflects dividend per share as a percent of Price. DNA does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.

DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future.  DNA does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.

DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. DNA does not pay a dividend, so it does not have a Dividend Growth rating .

YSG :  YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. DNA does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth

Price-Volume Data

Price: DNA closed on 9/5/2008 at $96.64 per share

Open : DNA opened trading at a price of $96.00 per share on 9/5/2008.

High : DNA traded at a High price of $97.00 per share on 9/5/2008.

Low : DNA traded at a Low price of $95.53 per share on 9/5/2008

Close : DNA closed trading at price $96.64 per share on 9/5/2008. (Close is also called Price in the VectorVest system)

Range : Range reflects the difference between the High and Low prices for the day. DNA traded with a range of $1.47 per share on 9/5/2008.

$Change : DNA closed up  0.14 from the prior day's closing Price.

%PRC : DNA's Price changed 0.15% from the prior day's closing price.

Volume : DNA traded 5,146,072 shares on 9/5/2008.

AvgVol : AvgVol is the 50 day moving average of daily volume as computed by VectorVest. DNA has an AvgVol of 5,441,200 shares traded per day.

%Vol : %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals ((Volume - AvgVol) / AvgVol ) * 100.  DNA had a %Vol of -5.42% on 9/5/2008

CI (Comfort Index) : CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. DNA has a CI rating of 0.91, which is fair on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.

Sales / Market Capitalization Information

Sales: DNA has annual sales of $12,176,000,000

Sales Growth : Sales Growth is the Sales Growth Rate in percent over the last 12 months.  DNA has a Sales Growth of 11.00% per year. This is good . Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.

Sales Per Share (SPS): DNA has annual sales of $11.53 per share . SPS can be used as a measure of valuation when comparing stocks within an Industry Group.

Price to Sales Ratio (P/S): DNA has a P/S of 8.38 . This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.

Shares: DNA has 1,055,000,000 shares of stock outstanding .

Market Capitalization: DNA has a Market Capitalization of $102,018,000,000 . Market Capitalization is calculated by multiplying price times shares outstanding

Summary

DNA is overvalued compared to its Price of $96.64 per share , has well above average safety , and is currently rated a Buy .

The basic strategy is to buy Low risk, High reward stocks. We suggest that Prudent investors buy enough High Relative Value, High Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you'll find that your risk will go down and your investment performance will improve.

Graphs

Genentech Inc Drug (Biomedical\Genetic)